289,117 Shares in Health Catalyst, Inc. (NASDAQ:HCAT) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 289,117 shares of the company's stock, valued at approximately $2,044,000. Raymond James Financial Inc. owned 0.48% of Health Catalyst at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Fred Alger Management LLC bought a new stake in shares of Health Catalyst during the 3rd quarter worth approximately $6,858,000. Point72 Asset Management L.P. raised its stake in shares of Health Catalyst by 69.4% during the third quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company's stock valued at $4,208,000 after acquiring an additional 211,805 shares in the last quarter. Impax Asset Management Group plc raised its stake in shares of Health Catalyst by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock valued at $19,442,000 after acquiring an additional 195,525 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Health Catalyst by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company's stock valued at $11,749,000 after purchasing an additional 66,896 shares during the period. Finally, State Street Corp grew its stake in Health Catalyst by 2.5% in the third quarter. State Street Corp now owns 1,163,754 shares of the company's stock worth $9,473,000 after purchasing an additional 28,251 shares in the last quarter. 85.00% of the stock is owned by institutional investors.

Remove Ads

Insider Activity at Health Catalyst

In other news, COO Daniel Lesueur sold 16,902 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total transaction of $76,397.04. Following the transaction, the chief operating officer now owns 216,250 shares in the company, valued at $977,450. This represents a 7.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Linda Llewelyn sold 6,442 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $5.80, for a total transaction of $37,363.60. Following the completion of the transaction, the insider now directly owns 92,260 shares of the company's stock, valued at $535,108. The trade was a 6.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 56,530 shares of company stock valued at $299,572 in the last ninety days. Corporate insiders own 2.50% of the company's stock.

Health Catalyst Stock Down 8.5 %

Shares of HCAT traded down $0.38 during midday trading on Thursday, hitting $4.07. 36,566 shares of the company's stock traded hands, compared to its average volume of 816,701. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $285.76 million, a price-to-earnings ratio of -3.01 and a beta of 1.41. Health Catalyst, Inc. has a 1 year low of $3.76 and a 1 year high of $9.24. The firm's fifty day moving average is $4.96 and its 200-day moving average is $6.78.

Wall Street Analyst Weigh In

Several brokerages have weighed in on HCAT. Royal Bank of Canada lowered their target price on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating for the company in a report on Thursday, February 27th. Stifel Nicolaus lowered their price objective on shares of Health Catalyst from $10.00 to $5.00 and set a "hold" rating for the company in a research note on Thursday, February 27th. Wells Fargo & Company dropped their target price on shares of Health Catalyst from $13.00 to $10.00 and set an "overweight" rating on the stock in a report on Tuesday, January 21st. Canaccord Genuity Group reduced their price target on shares of Health Catalyst from $11.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, January 21st. Finally, KeyCorp upgraded shares of Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective on the stock in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $9.27.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.